2024 Pébruari: Several new drugs and promising therapies, such as chimeric antigen receptor T-cell therapy, have ushered in a “renaissance” for lupus, according to a speaker at the symposium Basic and Clinical Immunology for the Busy Clinician.
According to Emily Littlejohn, DO, MPH, of the Cleveland Clinic, monoclonal antibodies and interferons are two additional potential treatments for systemic lupus erythematosus that have emerged since 2020.
“2020 is what many of us consider the lupus renaissance,” Littlejohn told attendees during the hybrid meeting. “This is a time where, finally, we had many drugs entering the armamentarium very quickly.”
Anjeun panginten hoyong maca: Terapi Sél T T di Cina
According to Littlejohn, there have been a lot of exciting new treatments for SLE since the quick approvals of belimumab (Benlysta, GSK), voclosporin (Lupkynis, Aurinia), and anifrolumab (Saphnelo, AstraZeneca). CAR T-cell therapy might be the most exciting of these.
“This is used in the oncology world—we have seen it in [B-cell acute lymphoblastic leukemia], [B-cell non-Hodgkin’s lymphoma] and mantel cell lymphoma,” Littlejohn said. “The question is: What about in our diseases?”
Littlejohn nyatakeun yén sakabéh pasien anu milu dina ulikan Jérman nu enrolled lima pasien kalawan involvement multi-organ éta bisa ngahontal kaayaan nu nephritis ceased. Littlejohn nambihan yén hasilna masihan harepan, tapi terapina henteu bébas résiko.
Anjeun panginten hoyong maca: Terapi CAR T Cell pikeun sababaraha myeloma di Cina
"Aya résiko ageung sindrom pelepasan sitokin - khususna ICANS - anu pikasieuneun pisan," saur anjeunna.
"Kuring pikir aya seueur janji di rohangan ieu, ngan ukur nimbangkeun lima pasien ieu [dirawat ku terapi sél CAR-T] sareng kumaha saéna," tambahna.
Alternatipna pikeun Terapi sél T-mobil are in development. These include litifilimab (BIIB059, Biogen), interferon—kinoid, obinutuzumab (Gazyva, Genentech) and iberdomide (Bristol Myers Squibb).
Interferon-kinoid gagal nyumponan titik tungtung dina uji coba penting, sareng masa depanna "teu pasti," saur Littlejohn.
Anjeun panginten hoyong maca: Biaya terapi CAR T Cell di Cina
"Litifilimab mimitina ditaliti dina pasien lupus kulit, jumlahna aya 132," saur Littlejohn. "Anu aranjeunna mendakan yén éta nyumponan titik-titik primér kalayan panurunan skor CLASI kulit dina minggu ka-16."
Salaku tambahan, ubar éta suksés ngirangan jumlah sendi dina panyakit aktip, numutkeun Littlejohn nyarios.
Tungtungna, obinutuzumab geus patepung titik tungtung primér na di penderita lupus nephritis, ceuk Littlejohn.
